- Hospital
- Air Disinfection
- Anesthesia Machines
- Automated External Defibrilators (AEDS)
- Early Mobilization Systems
- Digital Modular Operating Room
- Hygiene Equipment
- Medical Beds
- Medical Mattresses
- Matresses
- Modular OR Integration
- Modular Wall System
- Monitors
- Nebulizers
- Operating Lights
- Ceiling Supply Units
- Operating Tables
- Ventilators
- Cardiopulmonary
- Diagnostics
- Technical Support
- Medical Equipment
European Society of Anaesthesiology and Intensive Care (ESAIC) Recommends Noninvasive, Continuous Hemoglobin Monitoring
The European Society of Anaesthesiology and Intensive Care (ESAIC) highlight the value of noninvasive, continuous hemoglobin (Hb) monitoring in helping clinicians manage perioperative bleeding. Referencing studies using technologies such as Masimo SpHb®, the guidelines note that the use of noninvasive Hb-monitoring methods may be a practical approach to monitor the Hb concentration continuously and without accumulating additional blood losses.
In their summary of the guidance derived from their systematic literature review, the guidelines also note that when severe bleeding and volume shifts are expected or occurring, “continuous noninvasive haemoglobin monitoring may be considered for trend analyses and for reducing blood sampling for invasive laboratory measurement of haemoglobin concentration, especially in children.
Launched in 2008, Masimo SpHb® is part of the rainbow® Pulse CO-Oximetry platform, available on a variety of Masimo Pulse CO-Oximeters® and on devices from numerous third-party manufacturers, including Draeger, GE, Philips, and ZOLL. Utilizing multiple wavelengths of light, SpHb provides real-time, continuous visibility to changes in the hemoglobin trend between invasive blood samples.
As part of patient blood management programs, SpHb®has been found to improve outcomes in both high- and low-blood loss surgeries, such as reducing the percentage of patients receiving allogeneic transfusions,2,3 reducing the units of red blood cells transfused per patient,4-6 reducing the time to transfusion,7 reducing costs,8 and even reducing mortality 30 and 90 days after surgery by 33% and 29%, respectively (when combined with a goal-directed fluid therapy algorithm using Masimo PVi®).9 The evidence of SpHb®’s impact on outcomes spans the globe, now representing 7 countries on 4 different continents.2-10 Today, Masimo SpHb®technology supports clinicians and patient care in more than 75 countries.